Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19).

Version 1.0: Recommendations in this document are based on the latest available evidence on 12th March 2020. If using a printed copy the information is valid only on the day of printing. The document is subject to change in response to emerging new evidence; for the most recent version of the document please check: https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/guidanceforhealthcareworkers/
Scope

This document is intended for use by healthcare professionals. The recommendations are specific to the management of acute respiratory infection when SARS-CoV-2 COVID-19 infection is confirmed. While the recommendations are intended to strengthen clinical management of these patients they do not replace clinical judgment or specialist consultation.

Comprehensive information for members of the public and healthcare professional on the prevention, diagnosis and management COVID-19 is available from the following sources:


- Health Service Executive (HSE): [https://www2.hse.ie/conditions/coronavirus/coronavirus.html#Treatment](https://www2.hse.ie/conditions/coronavirus/coronavirus.html#Treatment)

- HSE Health Protection Surveillance Centre (HPSC): [https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/](https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/)

- World Health Organisation:
  - [https://www.who.int/health-topics/coronavirus](https://www.who.int/health-topics/coronavirus)
Specific Antiviral Therapy in SARS-CoV-2 (COVID-19)

There is a paucity of clinical evidence for any disease-specific treatment. However, there are a number of medicinal products under investigation and may be considered in severely ill patients or those at risk of severe disease. There are no comparative studies between different treatments; access to individual medicinal products may need consideration in the treatment selection process. See Tables 3-7 for information on medicinal products.

Treat empirically for community acquired pneumonia as per local guidelines and consider antivirals as below.

Table 1 lists criteria for specific antiviral therapy in SARS-CoV-2 (COVID-19). Clinical judgment will be required for all cases; specialist consultation with local Infectious Disease and Microbiology teams is recommended for those cases not meeting criteria listed in Table 1.

Table 1. Criteria for Specific Antiviral Therapy in SARS-CoV-2 (COVID-19)

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Details</th>
</tr>
</thead>
</table>

Consider treatment in patients with NEWS Score ≥4 and significant co-morbidities or risk factors for severe disease, including:

- Cardiovascular Disease
- Diabetes Mellitus
- Immunocompromised
- Chronic Kidney Disease
- Pre-existing Respiratory Disease
Table 2 Differential diagnoses of respiratory infections in presentation of suspected community transmission of Covid-19 (adapted from St James’s Hospital Protocol).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Investigations</th>
<th>Treatment</th>
</tr>
</thead>
</table>
| Community Acquired Pneumonia | - Arterial blood gases  
- Chest X-ray  
- Full Blood Count  
- Urea and electrolytes  
- Blood cultures  
- Sputum cultures  
- Urine for Legionella antigen | Treat according to local antimicrobial prescribing policy. |
| Healthcare Associated Pneumonia | - Arterial blood gases  
- Chest X-ray  
- Full Blood Count  
- Urea and electrolytes  
- Blood cultures  
- Sputum cultures  
- 12 lead ECG | Treat according to local antimicrobial prescribing policy. |
| Acute Infective Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) | - Arterial blood gases  
- Chest X-ray  
- Full Blood Count  
- Urea and electrolytes  
- Blood cultures  
- Sputum cultures  
- 12 lead ECG  
- Pulmonary Function Tests | Treat according to local antimicrobial prescribing policy. |
| Viral Influenza | - Arterial blood gases  
- Chest X-ray  
- Full Blood Count  
- Urea and electrolytes  
- Blood cultures  
- Sputum cultures  
- Nasopharyngeal aspirate | Treat according to local antimicrobial prescribing policy.  
**AND**  
| Suspected Covid-19 Infection | - Test as per most recent guidance from HPSC. | See Table 3. |
Table 3 Diagnostics and pharmacological management of patients with confirmed COVID-19 Infection (adapted from St James’s Hospital Protocol).

<table>
<thead>
<tr>
<th>Investigations</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed COVID-19 Infection.</td>
<td>Refer to Tables 4, 5, 6 and 7 for further information on individual medicinal products. There is a paucity of clinical evidence for the use of any medicinal product in the treatment of COVID-19. The following are experimental COVID-19 treatment options (used as monotherapy) in adults: There is no paediatric dosing available at this time. Where clinically appropriate, children ≥ 12 years may be considered for adult dosing. Listed alphabetically: - Chloroquine (oral): 500mg TWICE daily for 10 days (see Table 4) Note: Highly toxic in overdose, especially in children OR - Hydroxychloroquine (oral): Day 1: 400mg TWICE a day, then Days 2-5: 200mg TWICE a day (total duration 5 days). (see Table 5) Note: Highly toxic in overdose, especially in children OR - Lopinavir/ritonavir (oral) 400mg/100mg TWICE daily up to a maximum of 14 days. (see Table 6) OR - Remdesivir (intravenous): 200mg ONCE daily on Day 1, then 100mg ONCE daily for a total of 10 days. (available on Compassionate Use basis only from Gilead) (see Table 7)</td>
</tr>
</tbody>
</table>
Evidence Summary

COVID-19 is a novel coronavirus and there is very limited clinical evidence for the use of any medicinal product and there is currently no licensed treatment available. Recommendations in this document are based on the latest available evidence (as of 12th March 2020) which is summarised below.

Chloroquine

In the early in vitro studies, chloroquine was found to block COVID-19 infection. The anti-viral and anti-inflammatory activities of chloroquine may account for its potent efficacy in treating patients with COVID-19 pneumonia. A recent study by Wang et al. revealed that remdesivir and chloroquine were highly effective in the control of 2019-nCoV in vitro.

Lopinavir/ritonavir

One article reports that the use of Kaletra® for the treatment of SARS was associated with a better outcome. Zhang et al. also reported a successful case of MERS-CoV disease treated with triple combination therapy LPV/RTV, ribavirin, and IFN-alpha 2a. Currently, Zhang et al. recommend Kaletra® as part of triple therapy with ribavirin and interferon. Young et al. describes the use of Kaletra® in 5 out of 18 patients. Five patients were treated with Kaletra® within 1 to 3 days of desaturation, but evidence of clinical benefit was equivocal. While defervescence occurred within 1 to 3 days of Kaletra® initiation, it was unable to prevent progressive disease in 2 patients. Decline in viral load as indicated by the cycle threshold value from nasopharyngeal swabs also appeared similar between those treated and not treated with Kaletra.

Remdesivir

Reported to inhibit human and zoonotic coronavirus in vitro and to restrain severe acute respiratory syndrome coronavirus (SARS-CoV) in vivo. The antiviral activity of remdesivir and IFN-beta was found to be superior to that of LPV/RTV-IFN-beta against MERS-CoV in vitro and in vivo. In one case report (n=1), on hospital day 7 (illness day 11) following radiographic findings of atypical pneumonia remdesivir was administered. On hospital day 8 (illness day 12), the patient’s clinical condition improved. Nasopharyngeal & oropharyngeal specimens obtained on illness days 11 & 12 showed a trend toward decreasing levels of virus. Both these outcomes may be reflective of the virus burning out rather than specifically related to the efficacy of remdesivir. A small number of patients with COVID-19 have received intravenous remdesivir for compassionate use outside of a clinical trial setting. A randomized placebo-controlled clinical trial of remdesivir for treatment of hospitalized patients with pneumonia and COVID-19 has been implemented in China.

Risk Factors for Severe Disease

A number of potential risk factors, including advanced age and a high SOFA (Sequential Organ Failure Assessment) score, have been reported as possible factors to identify patients with poor prognosis at an early stage.
Drug-Drug Interactions

Clinically significant drug-drug interactions may occur with the medicinal products used to treat COVID-19. A thorough medication history (including alternative and herbal medicines) should be obtained prior to initiation of treatment. Refer to the Summary of Product Characteristics and drug-drug interaction databases (e.g. Stockley’s Interaction Checker) to check for drug-drug interactions. The University of Liverpool have developed an online database for checking drug-drug interactions with the experimental COVID-19 specific medicinal products; available online at www.covid19-druginteractions.org.

Dose Adjustments

Where a dose reduction is recommended in hepatic or renal impairment it is recommended to prescribe the upper end of the dose range in the context of acute respiratory infection with SARS-CoV-2 (COVID-19) to avoid under dosing.

Administration of Medicinal Products in the Treatment of COVID-19

Timely initiation of medicinal products used for the treatment of COVID-19, at the recommended dose and frequency, is recommended to maximise efficacy, or the development of viral resistance. Delayed or omitted doses should be avoided, unless on the advice of the treating physician.
### Table 4 Chloroquine for the treatment for confirmed COVID-19 (adapted from St James’s Hospital Protocol).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlicensed indication, recommended from expert consensus (published ahead of trial results).</td>
<td>A weak base that increases the endosomal pH of acidic vesicles required for virus/cell fusion as well as interfering with glycosylation of cellular receptors of SARS-CoV.</td>
<td>Known hypersensitivity to chloroquine or any of the excipients. Concomitant use with amiodarone (due to increased risk of ventricular arrhythmia; see also Drug Interactions)</td>
<td>Full Blood Count: Myelosuppression may occur rarely; monitor if pre-existing myelosuppressive or if receiving other myelosuppressive agents concomitantly. ECG: QTc prolongation may occur. Use with caution if pre-existing QTc prolongation and/or known risk factors for prolongation of the QTc interval (including concomitant administration of other QTc prolonging agents). Blood glucose: may cause hypoglycaemia. Epilepsy: may lower seizure threshold G6PD: Caution advised in patients with G6PD deficiency, may be risk of haemolysis. If status unknown, do not delay initiation of treatment in the context of moderate or severe COVID-19.</td>
<td>Renal Impairment: Use with caution. Dose reduced if CrCl &lt;10ml/min; use 50% of normal dose. For patients on continuous veno-venous hemodialysis (CVVHD) no dose adjustment is necessary - dose as in normal renal function. Hepatic Impairment: No dose adjustment recommended in Avloclor® Summary of Product Characteristics. Use with caution in hepatic impairment, particularly when associated with cirrhosis.</td>
<td>See Summary of Product Characteristics (SmPC) for full list of side-effects; available from: <a href="https://www.medicines.org.uk/emc/product/5490/smpc">https://www.medicines.org.uk/emc/product/5490/smpc</a>. Chloroquine is highly toxic in overdose and children are particularly susceptible to toxic side effects. Ref Medicines for Children 2003 RCPCH</td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online (<a href="http://www.covid19-druginteractions.org/">http://www.covid19-druginteractions.org/</a>)</td>
<td></td>
</tr>
<tr>
<td>Recommended Dose: Chloroquine phosphate 500mg twice daily for 10 days for patients diagnosed as mild, moderate and severe cases.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Details of availability and supply process to be confirmed. Tablets can be crushed and dispersed in water for administration. Bioavailability is increased when dose given with food. Without crushing they will disperse in one to five minutes (different brands may vary).*

---

Protocol: Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19)  
Protocol Code: COVID19  
Approved by: Dr Vida Hamilton, HSE National Clinical Advisor and Group Lead, Acute Hospitals  
Contributors: Prof C Bergin, M Philbin, P Gilvary, M O'Connor, F King  
Published: 13 Mar 2020  
Review: 30 Apr 2020  
Version number: 1.0  
Page 8 of 15

Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer). This information is valid only on the day of printing, for any updates please check: [https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/guidanceforhealthcareworkers/](https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/guidance/guidanceforhealthcareworkers/)
### Table 5 Hydroxychloroquine (HCQ) for the treatment for COVID-19.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlicensed indication, recommended from expert consensus (published ahead of trial results).</td>
<td>Chloroquine analogue (see Table 3). Reported to have anti-SARS-CoV activity <em>in vitro</em> suggesting potential pharmacological agent for the treatment of COVID-19 infection. <em>In vitro</em> study reported more potent inhibition of SARS-CoV-2 with HCQ compared to chloroquine.</td>
<td>Hypersensitivity to active ingredients or any of the excipients. Known hypersensitivity to 4-aminoquinoline compounds. Pre-existing maculopathy of the eye. Pregnancy. Children aged &lt;6 years of age (200mg tablets not adapted for weight &lt;35kg). Contd. next page</td>
<td>Full Blood Count: Myelosuppression may occur rarely; monitor if pre-existing myelosuppression or if receiving other myelosuppressive agents concomitantly. ECG: QTc prolongation may occur. Use with caution if pre-existing QTc prolongation and/or known risk factors for prolongation of the QTc interval (including concomitant administration of other QTc prolonging agents). Blood glucose: may cause hypoglycaemia. Epilepsy: may lower seizure threshold.</td>
<td>Renal Impairment: CrCl 30-50mL/min: 75% of dose CrCl 10-30mL/min: 25-50% of dose. CrCl &lt;10mL/min: 25-50% of dose. CVVHD: 25-50% of dose. Recommend using upper dose range in context of COVID-19 infection. Extending dose intervals rather than dose reductions may be necessary for practical reasons. Contd. next page</td>
<td>See Summary of Product Characteristics (SmPC) for full list of side-effects; available from: <a href="https://www.medicines.ie/medicines/plaquenil-tablets-33380/smpc">https://www.medicines.ie/medicines/plaquenil-tablets-33380/smpc</a></td>
<td>Hydroxychloroquine is highly toxic in overdose and children are particularly susceptible to toxic side effects. Ref Medicines for Children 2003 RCPCH Avoid concomitant use of HCQ with drugs known to induce retinal toxicity.</td>
<td>Available as Plaquenil® (Sanofi-Aventis) from All-Phar. Details of ordering process are pending confirmation and will be provided direct to Chief Pharmacists. No data available for enteral tube administration of tablet formulation.</td>
</tr>
<tr>
<td>Recommended Dose: Day 1: 400mg TWICE a day, then Days 2-5 200mg TWICE a day (total duration 5 days).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Protocol Code:** COVID19  
**Approved by:** Dr Vida Hamilton, HSE National Clinical Advisor and Group Lead, Acute Hospitals  
**Contributors:** Prof C Bergin, M Philbin, P Gilvary, M O’Connor, F King  
**Published:** 13 Mar 2020  
**Version number:** 1.0  
**Review:** 30 Apr 2020  
**Page:** 9 of 15

---

*This information is valid only on the day of printing, for any updates please check: https://www.hpsc.ie/a-z/respiratory/novelcoronavirus/guidance/guidanceforhealthcareworkers/*
Table 5 (continued from previous page) Hydroxychloroquine (HCQ) for the treatment for COVID-19.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Lapp lactase deficiency or glucose-galactose malabsorption.</td>
<td></td>
<td>G6PD: Caution advised in patient with G6PD deficiency, may be risk of haemolysis. If status unknown, do not delay initiation of treatment in the context of moderate or severe COVID-19.</td>
<td>Hepatic Impairment: No specific dose adjustments recommended – use with caution.</td>
<td>Caution if co-administering medicines which may cause adverse ocular or skin reactions</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HCQ may increase levels of ciclosporin and digoxin (monitor levels)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Caution with anti-convulsants; HCQ may lower seizure threshold</td>
<td></td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check: https://www.hpsc.ie/a-z/respiratory/coronavirus/hcov19/COVID19/guidance/guidanceforhealthcareworkers
Table 6 Lopinavir/ritonavir (Kaletra®) for the treatment for COVID-19 (adapted from St James’s Hospital Protocol).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/ritonavir (Kaletra®)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td>Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td>Unlicensed indication, recommended from expert consensus (published ahead of trial results).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Recommended Dose:</strong> lopinavir/ritonavir (Kaletra®) 400mg/100mg TWICE a day administered as: Kaletra® 200mg/50mg Tablets: TWO tablets TWICE a day (with or without food). OR Kaletra® (80mg/20mg per mL) Oral Solution: 5mL TWICE a day (with food).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Recommended Dose:</strong> lopinavir/ritonavir (Kaletra®) 400mg/100mg TWICE a day administered as: Kaletra® 200mg/50mg Tablets: TWO tablets TWICE a day (with or without food). OR Kaletra® (80mg/20mg per mL) Oral Solution: 5mL TWICE a day (with food).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td>Lopinavir and ritonavir were initially hypothesised to inhibit the 3-chymotrypsin-like protease of SARS and MERS. This combined agent has in vitro activity against the SARS-CoV and appears to have some activity against MERS-CoV in animal studies. The use of this agent for treatment of COVID-19 has been described in case reports.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Proposed MOA:</strong> Lopinavir and ritonavir are highly protein-bound; unlikely to be significantly removed by haemodialysis or peritoneal dialysis.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Contra-indications:</strong> Hypersensitivity to active ingredients or any of the excipients. Severe hepatic insufficiency. Co-administration with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Monitoring:</strong> Liver Function Tests (LFTs): deranged liver function tests and hepatic dysfunction have been reported; monitor LFTs before and during treatment. Renal Impairment: negligible renal clearance and increased plasma concentrations are not expected in renal impairment. Lopinavir and ritonavir are highly protein-bound; unlikely to be significantly removed by haemodialysis or peritoneal dialysis.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Side-Effects:</strong> Liver Function Tests (LFTs): deranged liver function tests and hepatic dysfunction have been reported; monitor LFTs before and during treatment. Renal Impairment: negligible renal clearance and increased plasma concentrations are not expected in renal impairment. Lopinavir and ritonavir are highly protein-bound; unlikely to be significantly removed by haemodialysis or peritoneal dialysis.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Drug-Drug interactions:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td><strong>Preparation &amp; Sourcing:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Refer to SmPC and drug-drug interaction databases e.g. Stockley’s and University of Liverpool online</td>
<td>Available as oral formulations only (tablets and oral solution). Contact wholesaler and specific form to be completed by the pharmacy department. Crushing tablets significantly reduces exposure of both lopinavir and ritonavir (↓AUC by 45% and 47% respectively). Avoid crushing lopinavir/ritonavir tablets, if possible.</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------</td>
<td>--------------------</td>
<td>------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Lopinavir/ritonavir (Kaletra®)</td>
<td>Contd. Kaletra® oral solution contains propylene glycol and 42% v/v alcohol; contraindicated in children &lt;14 days, pregnant women, patients with hepatic or renal failure and patients treated with disulfiram or metronidazole due to the potential risk of toxicity from the excipient propylene glycol.</td>
<td>Contd. Hepatic Impairment: Possible increased exposure in mild or moderate impairment; not expected to be clinically significant. Avoid in severe hepatic impairment.</td>
<td>Contd. Monitoring</td>
<td>Contd. Clinically significant drug-drug interactions are extensive. A thorough medication history (including alternative and herbal medicines) should be obtained prior to initiation of treatment.</td>
<td>Contd.</td>
<td>If the oral solution is not available and it is considered necessary to crush tablets; a consideration of increasing dose to THREE tablets TWICE a day may be reasonable (unlicensed dose). No data available for enteral tube administration of tablet formulation. Oral solution is preferable in patients unable to swallow solid dosage forms.</td>
<td></td>
</tr>
</tbody>
</table>

Table 6 (continued from previous page) Lopinavir/ritonavir (Kaletra®) for the treatment for COVID-19 (adapted from St James’s Hospital Protocol).

Protocol: Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19)

Protocol Code: COVID19

Approved by: Dr Vida Hamilton, HSE National Clinical Advisor and Group Lead, Acute Hospitals

Contributors: Prof C Bergin, M Philbin, P Gilvary, M O’Connor, F King

Published: 13 Mar 2020

Review: 30 Apr 2020

Version number: 1.0

Page 12 of 15

Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer). This information is valid only on the day of printing, for any updates please check: [https://www.hpsc.ie/a-g/respiratory/coronavirus/novelcoronavirus/guidance/guidanceforhealthcareworkers](https://www.hpsc.ie/a-g/respiratory/coronavirus/novelcoronavirus/guidance/guidanceforhealthcareworkers).
Table 7 Remdesivir for the treatment for COVID-19.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Proposed MOA in COVID-19</th>
<th>Key Information</th>
</tr>
</thead>
</table>
| Remdesivir | Remdesivir (GS-5734) is a phosphoramidate prodrug of an adenine derivative with a chemical structure similar to tenofovir alafenamide. | - Remdesivir is an investigational medicinal product only available on a compassionate use basis direct from the manufacturer (Gilead).  
- Requests for supply of this medicine must be submitted by the treating physician on an individual patient basis via the online portal: [https://rdvcu.gilead.com/](https://rdvcu.gilead.com/)  
- In order to access remdesivir a number of documents must be completed and submitted to the manufacturer. The following documents are required and may be prepared in advance to expedite the ordering process for individual patients:  
1. Signing of a Confidential Disclosure Agreement  
2. Signing of Prescriber Agreement  
3. Communication from Hospital CEO or Ethics Committee to approve the use of a Compassionate Access Medicine in the hospital  

Key Inclusion Criteria (subject to change at discretion of manufacturer):  
- Hospitalization  
- Confirmed SARS-CoV-2 by PCR  
- Mechanical ventilation  

Key Exclusion criteria include (subject to change at discretion of manufacturer):  
- Evidence of multi-organ failure  
- Pressor requirement to maintain blood pressure  
- ALT (alanine transaminase) levels > 5 x ULN (Upper Limit of Normal)  
- Creatinine Clearance <30 mL/min or dialysis or Continuous Veno-Venous Hemofiltration  
- Remdesivir cannot be used in conjunction with other experimental antiviral agents for COVID-19 (e.g., lopinavir/ritonavir)  

The above criteria are subject to change and requests may be subject to additional considerations and limitations. Further information is available on the online portal: [https://rdvcu.gilead.com/](https://rdvcu.gilead.com/)  
Contd. on next page

Unlicensed medicinal product, only available on compassionate use basis from manufacturer.  

Recommended Dose (as intravenous infusion):  
200mg on Day 1; then 100mg on Days 2-10 (total duration 10 days).  

Refer to the manufacturer’s information for reconstitution and administration details.  

Contd. on next page

Remdesivir (GS-5734) is a phosphoramidate prodrug of an adenine derivative with a chemical structure similar to tenofovir alafenamide.  

Broad-spectrum activities against RNA viruses such as MERS and SARS in vitro in cell cultures and animal models, and has been tested in a clinical trial for Ebola.  

Contd. on next page

Protocol: Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19)

Published: 13 Mar 2020  
Review: 30 Apr 2020  
Version number: 1.0

Protocol Code: COVID19  
Approved by: Dr Vida Hamilton, HSE National Clinical Advisor and Group Lead, Acute Hospitals  
Contributors: Prof C Bergin, M Philbin, P Gilvarry, M O'Connor, F King  
Page 13 of 15

Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)  
This information is valid only on the day of printing, for any updates please check: [https://www.hpsc.ie/a-z/respiratory/novelcoronavirus/guidance/guidanceforhealthcareworkers/](https://www.hpsc.ie/a-z/respiratory/novelcoronavirus/guidance/guidanceforhealthcareworkers/)
Other Medicinal Products in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19)

There is emerging data for medicinal products in the clinical management of COVID-19 that are not anti-viral in their mechanism of action. These would only be considered in the same clinical setting of an elevated NEWS score and only after discussion between critical care medicine and infection specialists.
References